Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finasteride plus testosterone undecanoate and anastrozole vs finasteride alone for benign prostatic hyperplasia
ChiCTR2600123281Phase 2Recruiting
- Sponsor
- Zunyi Medical University Affiliated Hospital
- Start
- Apr 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of finasteride, testosterone undecanoate and anastrozole in benign prostatic hyperplasia (BPH) (2 arms), sponsored by Zunyi Medical University Affiliated Hospital. Primary endpoints: Total Prostate Volume, International Prostate Symptom Score and 2 more. Started Apr 2026; status: recruiting.
02
Drugs
finasteridetestosterone undecanoateanastrozole
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on ChiCTR2600123281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123281.